Primaquine in vivax malaria: an update and review on management issues

Abstract Primaquine was officially licensed as an anti-malarial drug by the FDA in 1952. It has remained the only FDA licensed drug capable of clearing the intra-hepatic schizonts and hypnozoites of Plasmodium vivax . This update and review focuses on five major aspects of primaquine use in treatmen...

Full description

Bibliographic Details
Published in:Malaria Journal
Main Authors: Fernando Deepika, Rodrigo Chaturaka, Rajapakse Senaka
Format: Article in Journal/Newspaper
Language:English
Published: BMC 2011
Subjects:
Primaquine
Plasmodium vivax
Vivax Malaria
Prophylaxis
Radical cure
Arctic medicine. Tropical medicine
RC955-962
Infectious and parasitic diseases
RC109-216
Arctic
Online Access:https://doi.org/10.1186/1475-2875-10-351
https://doaj.org/article/ba0f58d8c7594b9c89ebf2fbf1c8b80a
Description
Summary:Abstract Primaquine was officially licensed as an anti-malarial drug by the FDA in 1952. It has remained the only FDA licensed drug capable of clearing the intra-hepatic schizonts and hypnozoites of Plasmodium vivax . This update and review focuses on five major aspects of primaquine use in treatment of vivax malaria, namely: a) evidence of efficacy of primaquine for its current indications; b) potential hazards of its widespread use, c) critical analysis of reported resistance against primaquine containing regimens; d) evidence for combining primaquine with artemisinins in areas of chloroquine resistance; and e) the potential for replacement of primaquine with newer drugs.

Similar Items